Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HMG-CoA reductase inhibitors' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 173 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Avorn, J
      Unhealthy ageing: functional and socioeconomic impact

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    2. Buckley, BM
      Healthy ageing: ageing safely

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    3. Gaw, A
      Healthy ageing: addressing acute coronary syndrome?

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    4. Blauw, GJ; Bollen, ELEM; van Buchem, MA; Westendorp, RGJ
      Dementia at old age: a clinical end-point of atherosclerotic disease

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    5. Sheehy, N; Vaughan, CJ; Delanty, N
      Statins and neuroprotection

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    6. Maciejko, JJ
      Clinical benefits from lowering cholesterol

      JOURNAL OF CLINICAL LIGAND ASSAY
    7. Martinez-Gonzalez, J; Raposo, B; Rodriguez, C; Badimon, L
      3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs - Balance between transcriptional and posttranscriptional regulation

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    8. Folzenlogen, D
      A case of atorvastatin combined toxic myopathy and inflammatory myositis

      JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
    9. Omar, MA; Wilson, JP; Cox, TS
      Rhabdomyolysis and HMG-CoA reductase inhibitors

      ANNALS OF PHARMACOTHERAPY
    10. Punthakee, Z; Scully, LJ; Guindi, MM; Ooi, TC
      Liver fibrosis attributed to lipid lowering medications: two cases

      JOURNAL OF INTERNAL MEDICINE
    11. Bernini, F; Poli, A; Paoletti, R
      Safety of HMG-CoA reductase inhibitors: Focus on atorvastatin

      CARDIOVASCULAR DRUGS AND THERAPY
    12. Stiles, KP; Abbott, KC; Welch, PG; Yuan, CM
      Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic

      CLINICAL NEPHROLOGY
    13. Wierzbicki, AS
      Synthetic statins: More data on newer lipid-lowering agents

      CURRENT MEDICAL RESEARCH AND OPINION
    14. Kurata, T; Kurata, M; Okada, T
      Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia

      JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
    15. Keane, WF; Brenner, BM; Mazzu, A; Agro, A
      The CHORUS (Cerivastatin in heart outcomes in renal disease Understanding survival) protocol: A double-blind, placebo-controlled trial in patients with ESRD

      AMERICAN JOURNAL OF KIDNEY DISEASES
    16. Coelho, OR; De Luca, IMS; Tanus-Santos, JE; Cittadino, M; Sampaio, RC; Coelho, OR; Hyslop, S; Moreno, H
      Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    17. Caroli-Bosc, FX; Le Gall, P; Pugliese, P; Delabre, B; Caroli-Bosc, C; Demarquary, JF; Delmont, JP; Rampal, P; Montet, JC
      Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation epidemiological - Study in an unselected population

      DIGESTIVE DISEASES AND SCIENCES
    18. van Dam, MJ; Penn, HJAM; den Hartog, FR; Kragten, HA; Trip, MD; Buirma, RJA; Kastelein, JJP
      A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: A randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease

      CLINICAL THERAPEUTICS
    19. Gibellato, MG; Moore, JL; Selby, K; Bower, EA
      Effects of lovastatin and pravastatin on cognitive function in military aircrew

      AVIATION SPACE AND ENVIRONMENTAL MEDICINE
    20. Balduini, W; De Angelis, V; Mazzoni, E; Cimino, M
      Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury

      STROKE
    21. Amin-Hanjani, S; Stagliano, NE; Yamada, M; Huang, PL; Liao, JK; Moskowitz, MA
      Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice

      STROKE
    22. Sterzer, P; Meintzschel, F; Rosler, A; Lanfermann, H; Steinmetz, H; Sitzer, M
      Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease

      STROKE
    23. Cucchiara, B; Kasner, SE
      Use of statins in CNS disorders

      JOURNAL OF THE NEUROLOGICAL SCIENCES
    24. Martinez-Gonzalez, J; Alfon, J; Berrozpe, M; Badimon, L
      HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independentlyof their effect on plasma cholesterol levels

      ATHEROSCLEROSIS
    25. Hunninghake, D; Insull, W; Toth, P; Davidson, D; Donovan, JM; Burke, SK
      Coadministration of colesevelam hydrochloride with atorvastatin lowers LDLcholesterol additively

      ATHEROSCLEROSIS
    26. Erl, W; Weber, KSC; Weber, PC; Weber, C
      Transient increase of monocyte adhesion after a single dose of simvastatin

      ATHEROSCLEROSIS
    27. Mostaza, JM; De la Piedra, C; Curiel, MD; Pena, R; Lahoz, C
      Pravastatin therapy increases procollagen IN-terminal propeptide (PINP), amarker of bone formation in post-menopausal women

      CLINICA CHIMICA ACTA
    28. Bogman, K; Peyer, AK; Torok, M; Kusters, E; Drewe, J
      HMG-CoA reductase inhibitors and P-glycoprotein modulation

      BRITISH JOURNAL OF PHARMACOLOGY
    29. Scharnagl, H; Schinker, R; Gierens, H; Nauck, M; Wieland, H; Marz, W
      Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells

      BIOCHEMICAL PHARMACOLOGY
    30. Durlach, V
      Statins: intervention studies facts and perspectives

      ANNALES D ENDOCRINOLOGIE
    31. Jones, SP; Lefer, DJ
      Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction

      ACTA PHYSIOLOGICA SCANDINAVICA
    32. Gentile, S; Turco, S; Guarino, G; Sasso, CF; Amodio, M; Magliano, P; Salvatore, T; Corigliano, G; Agrusta, M; De Simone, G; Gaeta, I; Oliviero, B; Torella, R
      Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

      DIABETES OBESITY & METABOLISM
    33. Guzman, ECR; Hirata, MH; Quintao, ECR; Hirata, RDC
      Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    34. Davidson, MH; Dicklin, MR; Maki, KC; Kleinpell, RM
      Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    35. Bourcier, T; Libby, P
      HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    36. Tonstad, S; Hjermann, I
      Cardiovascular risk factors and testing of relatives amongst patients withfamilial hyperlipidaemia one decade after a clinical trial

      JOURNAL OF INTERNAL MEDICINE
    37. Heuer, T; Gerards, H; Pauw, M; Gabbert, HE; Reis, HE
      Toxic liver damage through HMG-CoA-reductase inhibitors

      MEDIZINISCHE KLINIK
    38. Garmendia, F; Brown, AS; Reiber, I; Adams, PC
      Attaining United States and European guideline LDL-cholesterol levels withsimvastatin in patients with coronary heart disease (the GOALLS study)

      CURRENT MEDICAL RESEARCH AND OPINION
    39. Insull, W; Isaacsohn, J; Kwiterovich, P; Ma, P; Brazg, R; Dujovne, C; Shan, M; Shugrue-Crowley, E; Ripa, S; Tota, R
      Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial

      JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
    40. Axel, DI; Riessen, R; Runge, H; Viebahn, R; Karsch, KR
      Effects of cerivastatin on human arterial smooth muscle cell proliferationand migration in transfilter cocultures

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    41. Demetriou, D; Shabpar, A; Bohmig, G; Schmaldienst, S; Horl, WH; Watschinger, B
      Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation

      WIENER KLINISCHE WOCHENSCHRIFT
    42. Laufs, U; Gertz, K; Huang, P; Nickenig, G; Bohm, M; Dirnagl, U; Endres, M
      Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice

      STROKE
    43. Calmy, A; Lopez-Liuchi, JV; Borst, F; Meier, CA
      Comparison of current guidelines for the treatment of hypercholesterolaemia in secondary prevention: can the Swiss recommendations be simplified?

      SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT
    44. Akhmedzhanov, NM; Deyanda, DM; Perova, NV; Oganov, RG
      Lipid lowering activity of cerivastatin in patients with ischemic heart disease

      KARDIOLOGIYA
    45. Knapp, AC; Huang, JW; Starling, G; Kiener, PA
      Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death

      ATHEROSCLEROSIS
    46. Plosker, GL; Dunn, CJ; Figgitt, DP
      Cerivastatin - A review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia

      DRUGS
    47. Kusus, M; Stapleton, DD; Lertora, JJL; Simon, EE; Dreisbach, AW
      Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions

      AMERICAN JOURNAL OF THE MEDICAL SCIENCES
    48. Pruefer, D; Scalia, R; Lefer, AM
      Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    49. Duplaga, BA
      Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors

      ANNALS OF PHARMACOTHERAPY
    50. Taskinen, MR
      Strategies to treat CHD risk factors in type 2 diabetic patients

      ACTA DIABETOLOGICA
    51. Best, JD
      The role of atorvastatin in type 2 diabetic patients

      ACTA DIABETOLOGICA
    52. Warshafsky, S; Packard, D; Marks, SJ; Sachdeva, N; Terashita, DM; Kaufman, G; Song, K; Deluca, AJ; Peterson, SJ; Frishman, WH
      Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors forprevention of stroke

      JOURNAL OF GENERAL INTERNAL MEDICINE
    53. Fuhr, U
      "Clinically relevant" new drug interactions

      MEDIZINISCHE KLINIK
    54. Weizel, A
      Treatment with HMG-CoA reductase inhibitors - More than lipid lowering?

      HERZ
    55. Riessen, R; Axel, DI; Fenchel, M; Herzog, UU; Rossmann, H; Karsch, KR
      Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells

      BASIC RESEARCH IN CARDIOLOGY
    56. Ul Haq, I; Wallis, EJ; Jackson, PR; Yeo, WW; Ramsay, LE
      Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management

      JOURNAL OF HYPERTENSION
    57. Sasaki, J; Arakawa, K; Yamamoto, K; Kobori, S; Ageta, M; Kono, S
      A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.

      REVUE DE MEDECINE INTERNE
    58. Tsuji, A
      Tissue selective drug delivery utilizing carrier-mediated transport systems

      JOURNAL OF CONTROLLED RELEASE
    59. Corsini, A; Bellosta, S; Baetta, R; Fumagalli, R; Paoletti, R; Bernini, F
      New insights into the pharmacodynamic and pharmacokinetic properties of statins

      PHARMACOLOGY & THERAPEUTICS
    60. Tesfamariam, B; Frohlich, BH; Gregg, RE
      Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+release and vascular reactivity

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    61. Seed, M; Weir, MR
      Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin

      CLINICAL THERAPEUTICS
    62. Bottorff, MB; Yenkowsky, JP; Cave, DG
      Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy

      CLINICAL THERAPEUTICS
    63. Guijarro, C; Blanco-Colio, LM; Massy, ZA; O'Donnell, MP; Kasiske, BL; Keane, WF; Egido, J
      Lipophilic statins induce apoptosis of human vascular smooth muscle cells

      KIDNEY INTERNATIONAL
    64. Vaughan, CJ; Delanty, N
      Neuroprotective properties of statins in cerebral ischemia and stroke

      STROKE
    65. Bielecki, JW; Schraner, C; Briner, V; Kuhn, M
      Rhabdomyolysis and cholestatic hepatitis under treatment with simvastatin and chlorzoxazone

      SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT
    66. Diaz-Zagoya, JC; Asenjo-Barron, JC; Cardenas-Vazquez, R; Martinez, F; Juarez-Oropeza, MA
      Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet

      LIFE SCIENCES
    67. Jarvisalo, MJ; Toikka, JO; Vasankari, T; Mikkola, J; Viikari, JSA; Hartiala, JJ; Raitakari, OT
      HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease

      ATHEROSCLEROSIS
    68. Lanzarotto, F; Panarotto, B; Sorbara, R; Panteghini, M; Pagani, F; Sosta, S; Lanzini, A
      Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans

      GUT
    69. de Bont, N; Geijtenbeek, TBH; Netea, MG; Smilde, TJ; Demacker, PNM; Figdor, CG; van der Meer, JWM; Stalenhoef, AFH
      Integrin mediated adhesion of mononuclear cells from patients with familial hypercholesterolemia

      EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
    70. Liebhaber, MI; Wright, RS; Gelberg, HJ; Dyer, Z; Kupperman, JL
      Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors

      CHEST
    71. LLORENTECORTES V; MARTINEZGONZALEZ J; BADIMON L
      ESTERIFIED CHOLESTEROL ACCUMULATION INDUCED BY AGGREGATED LDL UPTAKE IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS IS REDUCED BY HMG-COA REDUCTASE INHIBITORS

      Arteriosclerosis, thrombosis, and vascular biology
    72. HOOGERBRUGGE N
      EFFECTS OF ATORVASTATIN ON SERUM-LIPIDS OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

      Journal of internal medicine
    73. NAKAMURA N; HAMAZAKI T; JOKAJI H; MINAMI S; KOBAYASHI M
      EFFECT OF HMG-COA REDUCTASE INHIBITORS ON PLASMA POLYUNSATURATED FATTY-ACID CONCENTRATIONS IN PATIENTS WITH HYPERLIPIDEMIA

      International journal of clinical & laboratory research
    74. Sirtori, CR; Bondioli, A; Murakami, T
      Microstatins: A new generation of potent cholesterol biosynthesis inhibitors with a reduced interaction potential - Focus on cerivastatin

      NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
    75. DAVIGNON J
      ADVANCES IN DRUG-TREATMENT OF DYSLIPIDEMIA - FOCUS ON ATORVASTATIN

      Canadian journal of cardiology
    76. MACNEIL P
      ECONOMIC-ASPECTS OF HYPERCHOLESTEROLEMIA TREATMENT WITH HMG-COA REDUCTASE INHIBITORS - A REVIEW OF RECENT DEVELOPMENTS

      Canadian journal of cardiology
    77. BLIZNAKOV EG; WILKINS DJ
      BIOCHEMICAL AND CLINICAL CONSEQUENCES OF INHIBITING COENZYME Q(10) BIOSYNTHESIS BY LIPID-LOWERING HMG-COA REDUCTASE INHIBITORS (STATINS) - A CRITICAL OVERVIEW

      Advances in therapy
    78. TANG YS; JONES L; SUNAY UB
      SYNTHESIS OF C-14-LABELED FLUVASTATIN (LESCOL(R))

      Journal of labelled compounds & radiopharmaceuticals
    79. GUIJARRO C; MASSY ZA
      HYPERLIPIDEMIA AS A PATHOGENIC FACTOR IN CHRONIC PROGRESSIVE RENAL-FAILURE

      Nefrologia
    80. TROCHE CJ; TACKE J; HINZPETER B; DANNER M; LAUTERBACH KW
      COST-EFFECTIVENESS OF PRIMARY AND SECONDARY PREVENTION IN CARDIOVASCULAR-DISEASES

      European heart journal
    81. CHRISTIANS U; JACOBSEN W; FLOREN LC
      METABOLISM AND DRUG-INTERACTIONS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITORS IN TRANSPLANT PATIENTS - ARE THE STATINS MECHANISTICALLY SIMILAR

      Pharmacology & therapeutics (Oxford)
    82. BHATNAGAR D
      LIPID-LOWERING DRUGS IN THE MANAGEMENT OF HYPERLIPIDEMIA

      Pharmacology & therapeutics (Oxford)
    83. CORSINI A; PAZZUCCONI F; ARNABOLDI L; PFISTER P; FUMAGALLI R; PAOLETTI R; SIRTORI CR
      DIRECT EFFECTS OF STATINS ON THE VASCULAR WALL

      Journal of cardiovascular pharmacology
    84. AVIRAM M; HUSSEIN O; ROSENBLAT M; SCHLEZINGER S; HAYEK T; KEIDAR S
      INTERACTIONS OF PLATELETS, MACROPHAGES, AND LIPOPROTEINS IN HYPERCHOLESTEROLEMIA - ANTIATHEROGENIC EFFECTS OF HMG-COA REDUCTASE INHIBITOR THERAPY

      Journal of cardiovascular pharmacology
    85. TAZUMA S; YAMASHITA G; OCHI H; MIURA H; KAJIHARA T; HATTORI Y; MIYAKE H; NISHIOKA T; HYOGO H; SUNAMI Y; YASUMIBA S; KAJIYAMA G
      EFFECTS OF CERIVASTATIN SODIUM, A NEW HMG-COA REDUCTASE INHIBITOR, ONBILIARY LIPID-METABOLISM IN PATIENTS WITH HYPERCHOLESTEROLEMIA

      Clinical therapeutics
    86. SASAKI J; ARAKAWA K; YAMAMOTO K; KOBORI S; AGETA M; KONO S
      A LONG-TERM COMPARATIVE TRIAL OF CERIVASTATIN SODIUM, A NEW HMG-COA REDUCTASE INHIBITOR, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA

      Clinical therapeutics
    87. Hatanaka, T; Honda, S; Sasaki, S; Katayama, K; Koizumi, T
      Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin

      JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS
    88. Bousquet, E; Amar, J; Salvador, M; Chamontin, B
      Cataract and HMG-CoA reductase inhibitor: a case report

      THERAPIE
    89. ENDRES M; LAUFS U
      HMG-COA REDUCTASE INHIBITORS AND THE RISK OF STROKE - NEW MECHANISM(S) INDEPENDENT OF CHOLESTEROL-LOWERING

      Nervenarzt
    90. PALOMAKI A; MALMINIEMI K; SOLAKIVI T; MALMINIEMI O
      UBIQUINONE SUPPLEMENTATION DURING LOVASTATIN TREATMENT - EFFECT ON LDL OXIDATION EX-VIVO

      Journal of lipid research
    91. BERGLUND L; WITZTUM JL; GALEANO NF; KHOUW AS; GINSBERG HN; RAMAKRISHNAN R
      3-FOLD EFFECT OF LOVASTATIN TREATMENT ON LOW-DENSITY-LIPOPROTEIN METABOLISM IN SUBJECTS WITH HYPERLIPIDEMIA - INCREASE IN RECEPTOR ACTIVITY, DECREASE IN APO-B PRODUCTION, AND DECREASE IN PARTICLE AFFINITY FOR THE RECEPTOR - RESULTS FROM A NOVEL TRIPLE-TRACER APPROACH

      Journal of lipid research
    92. NESS GC; CHAMBERS CM; LOPEZ D
      ATORVASTATIN ACTION INVOLVES DIMINISHED RECOVERY OF HEPATIC HMG-COA REDUCTASE-ACTIVITY

      Journal of lipid research
    93. DEBONT N; NETEA MG; ROVERS C; SMILDE T; DEMACKER PNM; VANDERMEER JWM; STALENHOEF AFH
      LPS-INDUCED CYTOKINE PRODUCTION AND EXPRESSION OF LPS-RECEPTORS BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA AND THE EFFECT OF HMG-COA REDUCTASE INHIBITORS

      Atherosclerosis (Amsterdam)
    94. CROUSE JR; BYINGTON RP; FURBERG CD
      HMG-COA REDUCTASE INHIBITOR THERAPY AND STROKE RISK REDUCTION - AN ANALYSIS OF CLINICAL-TRIALS DATA

      Atherosclerosis
    95. PITMAN WA; OSGOOD DP; SMITH D; SCHAEFER EJ; ORDOVAS JM
      THE EFFECTS OF DIET AND LOVASTATIN ON REGRESSION OF FATTY STREAK LESIONS AND ON HEPATIC AND INTESTINAL MESSENGER-RNA LEVELS FOR THE LDL RECEPTOR AND HMG COA REDUCTASE IN F1B HAMSTERS

      Atherosclerosis
    96. Contacos, C; Barter, PJ; Vrga, L; Sullivan, DR
      Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin

      ATHEROSCLEROSIS
    97. SIGURDSSON G; HARALDSDOTTIR SO; MELBERG TH; TIKKANEN MJ; MIETTINEN TE; KRISTIANSON KJ
      SIMVASTATIN COMPARED TO FLUVASTATIN IN THE REDUCTION OF SERUM-LIPIDS AND APOLIPOPROTEINS IN PATIENTS WITH ISCHEMIC-HEART-DISEASE AND MODERATE HYPERCHOLESTEROLEMIA

      Acta cardiologica
    98. MARAIS AD; FIRTH JC; BATEMAN ME; BYRNES P; MARTENS C; MOUNTNEY J
      ATORVASTATIN - AN EFFECTIVE LIPID-MODIFYING AGENT IN FAMILIAL HYPERCHOLESTEROLEMIA

      Arteriosclerosis, thrombosis, and vascular biology
    99. DART A; JERUMS G; NICHOLSON G; DEMDEN M; HAMILTONCRAIG I; TALLIS G; BEST J; WEST M; SULLIVAN D; BRACS P; BLACK D
      A MULTICENTER DOUBLE-BLIND, ONE-YEAR STUDY COMPARING SAFETY AND EFFICACY OF ATORVASTATIN VERSUS SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA

      Perfusion
    100. PERREAULT S; HAMILTON VH; LAVOIE F; GROVER S
      A HEAD-TO-HEAD COMPARISON OF THE COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITORS AND FIBRATES IN DIFFERENT TYPES OF PRIMARY HYPERLIPIDEMIA

      Cardiovascular drugs and therapy


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 08:20:05